DPYD PharmaKitDx

Kit for Qualitative Pharmacogenetic Analysis related to cancer treatment studies based on the detection of informative polymorphisms in the DPYD gene (DPYD*2A, DPYD*13, DPYD*hapB3 and D494V)

4x48 rxn

real-time PCR


  • Qualitative analysis that allows the detection of DPYD alleles:
    • DPYD*2A [NM_000110.4: c.1905+1G>A (rs3918290)]
    • DPYD*13 [NM_000110.4: c.1679T>G (rs55886062)]
    • DPYD*hapB3 [NM_000110.4: c.1129-5923C>G (rs75017182)]
    • DPYD-D949V [NM_000110.4: c.2846A>T (rs67376798)
  • Pharmacogenetic analysis associated with the response to fluoropyrimidine chemotherapy treatments, such as 5-fluorouracil (5-FU) and its prodrugs capecitabine and tegafur, offering an optional guide for dose adjustment in each case.
  • High sensitivity and specificity: The detection limit of 1 ng of genomic DNA.
  • Includes a heterozygous positive control for each of the variants of interest.
  • Validated using genomic DNA samples previously analyzed by sequencing techniques.
  • For in vitro diagnostic use only, aimed at professionals in the field of molecular biology.

Real-time PCR assay that uses a system of oligonucleotides and fluorescent hydrolysis probes that allow the specific detection of wild type polymorphisms and informative variants *2A, *13, *hapB3 (IVS10) and D949V of the DPYD gene in DNA samples human genomic.

  • Amount of DNA needed: 50 ng total
  • Type of sample: Peripheral blood (Germinal)
  • Number of reactions per sample: 4
  • Number of targets: 4
  • Manual work time: 15 min
  • Duration of the PCR program: 1h 30 min
  • Compatible cyclers: real-time PCR cycler with FAMTM and VICTM channel

DPYD PharmaKitDx

Fill in the form to request this kit.

Call us at +34 963 212 340

Or write to us at info@healthincode.com

"*" indicates required fields

This field is for validation purposes and should be left unchanged.